Physician profile
Mitchell J Donner
NPI 1922365733
$4,506.73
in general payments reported to CMS, 2019-2025
23 companies · $289 in 2025
The $289 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,203 · 2020: $195 · 2021: $139 · 2022: $65.88 · 2023: $158 · 2024: $1,457 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $996 · Food and Beverage: $880 · Education: $28.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $996.20 |
| Food and Beverage | $879.95 |
| Education | $28.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertiflex, INC. | $1,752.59 | 2019 | |
| Boston Scientific Corporation | $1,426.88 | 2019-2025 | Intracept, Superion Indirect Decompression System, General - Therapies |
| Abbott Laboratories | $256.91 | 2019-2025 | Eterna, Proclaim |
| Medtronic, INC. | $242.31 | 2021-2025 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $200.84 | 2019-2021 | |
| Medtronic USA, INC. | $117.20 | 2019 | |
| Stimwave Technologies Incorporated | $89.25 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $79.02 | 2022-2024 | Belbuca |
| Biodelivery Sciences International, INC. | $40.59 | 2019-2020 | |
| Foundation Fusion Solutions, LLC | $36.45 | 2024-2025 | |
| Nalu Medical, INC. | $35.83 | 2025 | Nalu Neurostimulation System |
| Relievant Medsystems, INC. | $30.48 | 2023 | Intracept |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.17 | 2024 | Relistor |
| Spr Therapeutics, INC | $23.69 | 2025 | Sprint Pns System |
| Vertex Pharmaceuticals Incorporated | $23.54 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.02 | 2024 | |
| Ibsa Pharma INC. | $19.60 | 2024 | Tirosint, Licart |
| Biohaven Pharmaceutical Holding Company LTD. | $18.02 | 2022 | |
| Pfizer INC. | $15.51 | 2020 | |
| Orthogenrx INC. | $15.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.18 | 2023 | Seglentis |
| Nevro Corp. | $11.26 | 2019 | |
| Amniox Medical, INC. | $10.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Donner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.